CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $55.13M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 0.59: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
55.13MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.61xvs all stocks
52-Week Change
7.73%vs all stocks
Market Capitalization
55.13MUSDvs all stocks (USD)
Enterprise Value
5.50MUSDvs all stocks (USD)
Forward P/E
-1.37xvs Biotechnology peers
Price to Book (MRQ)
1.04xvs Biotechnology peers
Enterprise to EBITDA
-0.1270xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-35.83%vs Biotechnology peers
Return on Equity (TTM)
-56.19%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 9, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-43.50MUSDvs all stocks (USD)
Net Income (TTM)
-40.23MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-32.79MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-23.80MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 9, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-39.70MUSDvs all stocks (USD)
Pre-tax Income
-36.12MUSDFY2025 · Dec 31, 2025Net Income
-36.12MUSDFY2025 · Dec 31, 2025EBIT
-39.70MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-39.69MUSDFY2025 · Dec 31, 2025Research & Development
31.86MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
7.85MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.38MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.3800USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.3800USDFY2025 · Dec 31, 2025Basic Shares Outstanding
95.19MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
95.19MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-36.12MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-31.79MUSDFY2025 · Dec 31, 2025Free Cash Flow
-31.82MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
66.00MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-36.12MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
16.25KUSDFY2025 · Dec 31, 2025Stock-based Compensation
1.33MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.00MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
1.10MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-107.32KUSDFY2025 · Dec 31, 2025Capital Expenditures
-33.95KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-2.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-33.95KUSDFY2025 · Dec 31, 2025Other Financing Charges
-15.27KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-15.27KUSDFY2025 · Dec 31, 2025Shares Outstanding
91.88MSharesUpdated Jul 9, 2026Float Shares
42.82MSharesUpdated Jul 9, 2026Shares Short
896.06KSharesUpdated Jul 9, 2026Short Ratio
1.35daysvs all stocks
Short % of Shares Outstanding
1.12%vs all stocks
% Held by Insiders
1.25%vs all stocks
% Held by Institutions
81.31%vs all stocks
Total Cash (MRQ)
54.53MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.5930USDUpdated Jul 9, 2026Total Debt (MRQ)
282.42KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0054xvs Biotechnology peers
Current Ratio (MRQ)
8.96xvs Biotechnology peers
Book Value per Share (MRQ)
0.5680USDUpdated Jul 9, 2026Total Assets
68.49MUSDvs all stocks (USD)
Total Current Assets
68.35MUSDFY2025 · Dec 31, 2025Total Liabilities
8.02MUSDFY2025 · Dec 31, 2025Total Non-current Assets
140.07KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
8.02MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
66.00MUSDFY2025 · Dec 31, 2025Accounts Payable
2.53MUSDFY2025 · Dec 31, 2025Short-term Debt
112.06KUSDFY2025 · Dec 31, 2025Other Current Liabilities
38.97KUSDFY2025 · Dec 31, 2025Long-term Debt
0.00USDFY2025 · Dec 31, 2025Common Stock (Book)
91.88KUSDFY2025 · Dec 31, 2025Retained Earnings
-130.90MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
60.47MUSDvs all stocks (USD)
52-Week Low
0.5600USDUpdated Jul 9, 202652-Week High
3.62USDUpdated Jul 9, 202652-Week Change
7.73%vs all stocks
Beta
1.61xvs all stocks
50-Day MA
2.25USDUpdated Jul 9, 2026200-Day MA
1.79USDUpdated Jul 9, 2026Avg 10-Day Volume
3.17MSharesUpdated Jul 9, 2026Avg 30-Day Volume
1.50MSharesUpdated Jul 9, 2026Diluted EPS (TTM)
-0.4200USDUpdated Jul 9, 2026Other Income / Expense
200.47KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 8.96Altman Z-Score: 0.59
Financial Health
Altman Z-Score 0.59: distress zoneCritical
Altman Z-Score: 0.59
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $55.13M, lower than 95% of all stocks globallySignificant
Market cap (USD): 55,127,508Global P5: 269,387,740.27
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Kala Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
SkinBioTherapeutics Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Poolbeg Pharma plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Curiosis Inc.
Tier 1ProductionApproval-Gated PipelineRule
Eco Animal Health Group PLC
Tier 1ProductionApproval-Gated PipelineRule
Creo Medical Group plc
Tier 1ProductionApproval-Gated PipelineRule
ImmuPharma PLC
Tier 1ProductionApproval-Gated PipelineRuleRisk
Bonus BioGroup Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Y-Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Faron Pharmaceuticals Oy
Tier 1ProductionApproval-Gated PipelineRuleRisk